Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non‐small cell lung cancer

by James E. Han, Shaakir Hasan, J. Isabelle Choi, Robert H. Press, Charles B. Simone II
Published 2021-09-01

Longitudinal Quantitative Analysis of Radiation Oncology Staff Illness in a New York City Center during COVID-19: The Impact of New Guidelines on Operations and Employee Health

by Shaakir Hasan, DO, Robert H. Press, MD, Arpit Chhabra, MD, J. Isabelle Choi, MD, Charles B. Simone II, MD
Published 2020-08-01

Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery

by Narottam Lamichhane, Thirupandiyur S. Udayakumar, Warren D. D’Souza, Charles B. Simone II, Srinivasa R. Raghavan, Jerimy Polf, Javed Mahmood
Published 2018-01-01

A National Survey of Radiation Oncology Experiences Completing Tele-Consultations During the Coronavirus Disease (COVID-19) Pandemic

by Arpit M. Chhabra, MD, Mudit Chowdhary, MD, J. Isabelle Choi, MD, Shaakir Hasan, DO, Robert H. Press, MD, Charles B. Simone, II, MD
Published 2021-01-01

Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?

by Shaakir Hasan, Daniel Gorovets, Eric J. Lehrer, Stanislav Lazarev, Robert H. Press, Madhur Garg, Keyur J. Mehta, Arpit M. Chhabra, J. Isabelle Choi, Charles B. Simone, II
Published 2021-01-01

Particle therapy for non-small cell lung tumors: where do we stand?A systematic review of the literature

by Krista eWink, Erik eRoelofs, Timothy eSolberg, Liyong eLin, Charles B. Simone II, Annika eJakobi, Christian eRichter, Christian eRichter, Philippe eLambin, Esther G.C. Troost
Published 2014-10-01

Machine learning highlights the deficiency of conventional dosimetric constraints for prevention of high-grade radiation esophagitis in non-small cell lung cancer treated with chem...

by José Marcio Luna, Hann-Hsiang Chao, Russel T. Shinohara, Lyle H. Ungar, Keith A. Cengel, Daniel A. Pryma, Chidambaram Chinniah, Abigail T. Berman, Sharyn I. Katz, Despina Kontos, Charles B. Simone, II, Eric S. Diffenderfer
Published 2020-05-01

NRG Oncology Survey of Monte Carlo Dose Calculation Use in US Proton Therapy Centers

by Liyong Lin, PhD, Paige A. Taylor, MS, Jiajian Shen, PhD, Jatinder Saini, PhD, Minglei Kang, PhD, Charles B. Simone, II, MD, Jeffrey D. Bradley, MD, Zuofeng Li, DSc, Ying Xiao, PhD
Published 2021-05-01

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

by Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael D. Offin, Andrew Jackson, Abraham J. Wu, Daphna Y. Gelblum, Ellen D. Yorke, Charles B. Simone II, Jamie E. Chaft, Matthew D. Hellmann, Daniel R. Gomez, Andreas Rimner, Joseph O. Deasy
Published 2020-07-01

Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers

by Robert H. Press, MD, Richard L. Bakst, MD, Sonam Sharma, MD, Rafi Kabarriti, MD, Madhur K. Garg, MD, MBA, Brian Yeh, MD, Daphna Y. Gelbum, MD, Shaakir Hasan, DO, J. Isabelle Choi, MD, Chris A. Barker, MD, Arpit M. Chhabra, MD, Charles B. Simone II, MD, FACRO, Nancy Y. Lee, MD, FASTRO
Published 2021-06-01

A Multi-Institutional Experience of Proton Beam Therapy for Sinonasal Tumors

by Nathan Y. Yu, MD, Mauricio E. Gamez, MD, William F. Hartsell, MD, Henry K. Tsai, MD, George E. Laramore, MD, PhD, Gary L. Larson, MD, Charles B. Simone, II, MD, Carl Rossi, MD, Sanford R. Katz, MD, Matthew R. Buras, MS, Michael A. Golafshar, MS, Carlos E. Vargas, MD, Samir H. Patel, MD
Published 2019-10-01

Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC

by Annemarie F. Shepherd, MD, Anthony F. Yu, MD, Michelle Iocolano, MD, Jonathan E. Leeman, MD, Aaron T. Wild, MD, Brandon S. Imber, MD, MA, Jamie E. Chaft, MD, Michael Offin, MD, James Huang, MD, James M. Isbell, MD, MSCI, Abraham J. Wu, MD, Daphna Y. Gelblum, MD, Narek Shaverdian, MD, Charles B. Simone, II, MD, Daniel Gomez, MD, Ellen Yorke, PhD, Andrew Jackson, PhD, Andreas Rimner, MD
Published 2021-08-01

Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-s...

by Melissa A.L. Vyfhuis, MD PhD, Neha Bhooshan, MD PhD, Whitney M. Burrows, MD, Michelle Turner, NP, Mohan Suntharalingam, MD MBA, James Donahue, MD, Elizabeth M. Nichols, MD, Josephine Feliciano, MD, Søren M. Bentzen, PhD DMSc, Shahed Badiyan, MD, Shamus R. Carr, MD, Joseph Friedberg, MD, Charles B. Simone, II, MD, Martin J. Edelman, MD, Steven J. Feigenberg, MD, Pranshu Mohindra, MD
Published 2017-07-01